Cambridge, MA, US. The Associate Director, Epidemiology and RWE Sciences will support pre- and post-launch evidence generating activities across entire product portfolios within a Therapeutic Area. The role will be responsible for helping map out integrated evidence generation activities for a product and then designing, reviewing and supporting the execution of evidence generating activities using primary and secondary data, as … Read more
Tokyo, Japan. l 部門機能 •IQVIAのコアアセットである医療ビッグデータ、及びテクノロジーを駆使した革新的新薬の市販後観察研究、PMS、Health Economics & Outcome Research(HEOR)研究などのエビデンスジェネレーションを推進 l 業務内容 •Real World Evidence(RWES)を使用した複数のプロジェクトのマネジメントや他領域におけるRWESを実務としたプロジェクトチームのリードやチームの参画 -与えられたリソースを基に、プロジェクトの目標を達成/成功させるべく企画からマネジメントまで運営 -詳細な情報を記した専門的な文書（例：RWE Study Protocols and Statistical Analysis Plans）の発展をリード -高品質な調査と分析を遂行するようチームを先導し、クライアントやステークホルダーに全てのプロジェクトにおいて高い品質と成功をコミット -クライアントの新規事業開発における識別と道筋を示し、事業の発展に寄与 l 応募要件 【 必須要件 】 •多様な規模と難度の業務に優先順位をつけ、マネジメントする能力 •高度な専門知識を持つ専門家で構成されたプロジェクトチームをリードした経験 •高度な文章力、コミュニケーション能力、Client influencing能力（例：高度なプレゼンテーション、会議の仕切り、ワークショップの促進、ビジネスや事業報告書の作成などの実績） •分析力、説明能力、問題解決力とそれらを示す実績 •製薬をはじめとしたライフサイエンス業界の主要問題や最新の動向の知識 •ヘルスケアコンサルティングやライフサイエンス産業における幅広いご経験、もしくは学術的経験と実績 【 以下の方歓迎 】 •コンサルティングとしてのメソッドの知識、ツールや技術をお持ちの方 •理系・工学系の修士をお持ちの方。もしく統計学・情報学の大学院資格をお持ちの方 •プログラミング言語: R, SAS l 語学力 日本語：ネイティブレベル 英語：ビジネスレベル（Writing , Speaking, Reading） l 勤務地 品川オフィス IQVIA is a leading global provider of … Read more
Beijing / Shanghai, China. RWE is increasingly important in China. Takeda China Medical has conducted several real-world studies (RWS). We hope the candidate provides HEOR&RWE and TAs with their experience and technical support. Key roles & responsibilities of Accelerator: 1. To learn China’s RWD resources and RWE development (overall picture such as Data status).2. To share RWE experience of candidate’s … Read more
US. The Sr. Manager, Health Economics and Outcomes Research (HEOR) & Real-World Evidence will be responsible for supporting the development and execution of global HEOR and RWE activities to support the Binding Site’s existing portfolio and pipeline products. This individual will play a key role in developing and executing HEOR/RWE strategies and will also assume a critical leadership role in … Read more
Raritan, NJ, US. The Global Commercial Strategy Organization is recruiting for a Director, Global Real World Evidence (RWE) Data Science Analytics in Global Commercial Data Science (GCDS). The position is based in Raritan, NJ and will require up to 25% travel. The Director Global RWE Data Science Analytics will lead the execution of industry leading RWE solutions across the GCDS … Read more
West Chester, PA US. The Associate Director, Real World Evidence Strategy is responsible for assessment of data needs/gaps, and identifying potential opportunities of using real world data to support all phases of drug development and commercial opportunities at Teva. Key activities include but are not limited to proactive identification and recommendation of new RWD sources and developing the road map … Read more
Seoul, South Korea. Works directly with clients to provide value added input, to develop business opportunities that will lead to additional starbursts and to deliver projects built around strategic issues. Has responsibility for ensuring delivery of high levels of client satisfaction. Typically works within a specific CoE area but may have responsibility across multiple expertise areas and/or clients. Meets or … Read more
Munich, Germany. We are seeking highly qualified candidates to fill the position: Global Oncology HEOR & RWE, Senior Manager (m/f/x). The Senior Manager, Global Health Economics Outcomes Research (HEOR) and Real World Evidence (RWE) reports to the Director Global HEOR ENHERTU leader and will work cross-functionally to implement HEOR and evidence generation projects. The person will work with other teams … Read more
Amsterdam, Netherlands. Ter versterking van ons team van consultants zijn wij op zoek naar een Healthcare consulent met expertise in Market Access in Nederland . Het team bestaat uit professionals met verschillende achtergronden en expertises, zoals: HTA, epidemiologie en market access. Met onze multidimensionale oplossingen en aanbiedingen zijn we toegewijd om de gezondheidszorg vooruit te helpen. Om onze bijdrage aan … Read more
London, UK. As part of the wider Real-World Evidence (RWE) team Lumanity is currently building a RWE Data Luminary Consulting Practice. This practice has been started as our clients have unique challenges which require RWE. For example, understanding treatment patterns/patient journeys, drug utilization studies, effectiveness of standard of care/generating synthetic controls, outcomes research, cost of illness, burden of disease, and … Read more
Hyderabad, India. The Principal Real World Evidence (RWE) Research Analyst is responsible for the scientific and methodological aspects of all RWE projects as well as providing guidance for other team members. Key Responsibilities: • Produce analytic results including full study reports for RWE or observational database analyses projects.• Independently draft and edit documents such as high level research proposals, protocols … Read more
Seoul, South Korea. Responsibilities: • Carry out work relating to the HEOR business areas (longitudinal retrospective study using internal or external big data, longitudinal prospective observational study, cross-sectional survey of patients/healthcare provider/or payers, patient reported outcome report, etc). • Work with supervision, indepently and/or as part of a project team on defined tasks. • Involve in business development/internal initiatives i.e. … Read more
Bangalore, India. The GHEOR department, which sits in the Global Medical Affairs department, is seeking Associate/Director, Real World Evidence Strategy. The role and level to be determined, commensurate with experience. The Associate/Director, Real World Evidence Strategy is responsible for assessment of data needs/gaps, and identifying potential opportunities of using real world data to support all phases of drug development and … Read more
Raritan, NJ, US / Beerse, Belgium. Other locations: Basel, Switzerland. We are looking for a Director Market Access Analytics and Real-World Evidence and (MAA & RWE). Responsible for the implementation of MAA & RWE strategies to meet the needs of increasingly evidence driven and cost-conscious HTA agencies around the world. The Director provides functionally robust evidence to inform and complement that generated … Read more
US. Cytel is seeking a highly skilled and motivated Senior Research Consultant specializing in Real-World Evidence (RWE) to join our dynamic team. The Senior Research Consultant will play a pivotal role in designing and executing RWE studies, providing valuable insights to our clients, and contributing to the advancement of evidence-based decision-making in healthcare. Responsibilities: Collaborate with cross-functional teams to develop … Read more
Real-World Evidence in Health Economics
Real-world evidence (RWE) has become an increasingly important aspect of health economics research in recent years. It provides a comprehensive and in-depth understanding of how different health interventions work in real-world settings.
What is Real-World Evidence?
Real-world evidence (RWE) is defined as data collected from sources other than traditional randomized controlled trials (RCTs). These data come from a variety of sources, including electronic health records (EHRs), claims databases, registries, patient-reported outcomes (PROs), and surveys.
RWE allows researchers to evaluate the effectiveness, safety, and cost-effectiveness of health interventions in real-world settings. This is important because RCTs often have strict inclusion and exclusion criteria, which means that the results may not be generalizable to real-world populations.
Importance of Real-World Evidence in Health Economics
RWE is becoming increasingly important in health economics because it provides a more complete picture of the effectiveness and safety of health interventions. By using RWE, researchers can evaluate how interventions work in a variety of settings and patient populations, which can help inform clinical practice and policy decisions.
RWE can also be used to conduct cost-effectiveness analyses, which help policymakers determine the value of health interventions. Cost-effectiveness analyses compare the costs and benefits of different health interventions, taking into account the costs of the intervention as well as the costs of any adverse events or complications that may occur.
Differences between RWE and Randomized Controlled Trials (RCTs)
RCTs are considered the gold standard for evaluating the effectiveness and safety of health interventions. However, there are several key differences between RWE and RCTs.
RCTs are conducted under controlled conditions and have strict inclusion and exclusion criteria, which means that the results may not be generalizable to real-world populations. RWE, on the other hand, is collected from a variety of sources and reflects the real-world experiences of patients.
RCTs also tend to be shorter in duration than RWE studies, which means that they may not capture the long-term effects of health interventions. RWE studies, on the other hand, can provide information on the long-term effectiveness and safety of interventions.
Methods of Collecting RWE
There are several methods of collecting RWE, including:
Electronic Health Records (EHRs)
EHRs are digital records of patient health information that are maintained by healthcare providers. EHRs can provide a wealth of information on patient demographics, diagnoses, treatments, and outcomes.
Claims databases contain information on healthcare services and medications that are billed to insurance providers. Claims data can provide information on healthcare utilization, costs, and outcomes.
Registries are databases that collect information on specific diseases or health conditions. They can provide valuable information on disease prevalence, treatment patterns, and outcomes.
Patient-Reported Outcomes (PROs)
PROs are questionnaires or surveys completed by patients that assess their health status, symptoms, and quality of life. PROs can provide information on patient preferences and experiences with different interventions.
Surveys can be used to collect information on patient demographics, health behaviors, and healthcare utilization. They can also be used to assess patient preferences and satisfaction with different interventions.
Advantages of Real-World Evidence
There are several advantages of using RWE in health economics research, including:
- RWE reflects real-world experiences and can provide a more comprehensive understanding of the effectiveness and safety of interventions.
- RWE can be used to evaluate interventions in a variety of settings and patient populations.
- RWE can provide information on the long-term effectiveness and safety of interventions.
- RWE can be used to conduct cost-effectiveness analyses, which can inform clinical practice and policy decisions.
Challenges and Limitations of Real-World Evidence
There are several challenges and limitations to using RWE in health economics research, including:
- RWE can be subject to bias and confounding, which can affect the validity of the results.
- RWE can be difficult to collect and analyze, particularly when using multiple data sources.
- RWE may not be as well-suited for evaluating rare diseases or interventions.
Applications of Real-World Evidence
RWE has several applications in health economics research, including:
Health Technology Assessment
Health technology assessment (HTA) is a process that evaluates the clinical effectiveness, safety, and cost-effectiveness of new health technologies. RWE can be used in HTA to provide information on the real-world effectiveness and safety of interventions.
Comparative Effectiveness Research
Comparative effectiveness research (CER) compares the effectiveness of different interventions for the same health condition. RWE can be used in CER to compare the effectiveness of interventions in different patient populations and settings.
Post-marketing surveillance is the process of monitoring the safety and effectiveness of new drugs and medical devices after they have been approved for use. RWE can be used in post-marketing surveillance to monitor the long-term safety and effectiveness of interventions.
Future of Real-World Evidence in Health Economics
RWE is likely to become increasingly important in health economics research in the future. Advances in technology and data analytics are making it easier to collect and analyze RWE, and policymakers are recognizing the importance of using RWE to inform clinical practice and policy decisions.